http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113181227-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac31afbea1cbbb03498644721ffb4a62 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-284 |
| filingDate | 2021-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5142f9610617e9d1c9ad77b5ff032c85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e3701ee8c7a567c08e4d8d5c091e2b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bb332410376520edc39232677bb8c58 |
| publicationDate | 2021-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113181227-A |
| titleOfInvention | Application of rhizoma atractylodis, magnolia officinalis and compatibility of rhizoma atractylodis and magnolia officinalis in preparation of medicine for preventing and treating podocyte injury type glomerular disease |
| abstract | The invention provides an application of rhizoma atractylodis, magnolia officinalis and the compatibility of the rhizoma atractylodis and the magnolia officinalis in preparing a medicine for preventing and treating podocyte injury type glomerular diseases. Specifically, the present invention discloses: the atractylodes rhizome, the magnolia bark and the compatibility thereof have obvious prevention and improvement effects on glomerular dysfunction, tissue structure damage, proteinuria generation, podocyte damage and podocyte insulin signal channel damage; the rhizoma atractylodis, the magnolia officinalis and the compatibility thereof promote the insulin sensitivity of podocytes, recover the function of the podocytes and inhibit the generation of proteinuria by regulating Sirt1/p53/miR-221 signal channels. The rhizoma atractylodis, the magnolia officinalis, the compatible extract of the rhizoma atractylodis and the magnolia officinalis are matched with related auxiliary materials, and the medicine for pertinently preventing and treating the glomerular diseases can be prepared by a conventional preparation method, so that a new treatment means and thought are provided for the diseases related to the glomerular podocyte injury. |
| priorityDate | 2021-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 168.